The UK and US have agreed to a key bilateral deal that will keep no tariffs on UK pharmaceutical shipments entering the American market.
The Terms of the Pact
Under the terms of the agreement, the UK has agreed to raise funding on pharmaceuticals through the National Health Service (NHS). This pledge guarantees that import taxes on these key exports will stay at nothing for a period of the next three years.
This agreement follows previous threats to significantly raise import taxes on branded pharmaceutical products, with potential rates discussed reaching double the cost.
"This agreement with the United Kingdom strengthens the international landscape for cutting-edge drugs and establishes much-needed fairness to U.S.–U.K. drug exports," a release said.
Economic Significance
Medicines represent one of the Britain's biggest exports to the US, which is by far the primary market for leading UK drugmakers.
Statistics indicate that in the one-year period to the end of the third quarter, the UK sold drugs totaling over eleven billion pounds to the US. This amount represented 17.4% of all goods exports in that period.
"This agreement safeguards jobs, stimulates investment and sets the stage for the UK to establish itself as a worldwide center for biotech and pharma," a government official remarked.
Detailed British Pledges
The agreement involves several key pledges from the UK:
- Revised Affordability Limit: The UK will increase the affordability limit at which it considers new medicines to be prohibitively costly by twenty-five percent.
- Higher Drug Budget: There is a aim to double overall NHS spending on drugs from 0.3% of Gross Domestic Product to 0.6% over the next decade.
- Payback Limit: The amount pharmaceutical firms must refund to the NHS to prevent overspending will be restricted at fifteen percent. Previously, repayments were more than 20%.
Recent Tensions
This agreement takes place against a protracted row between the pharmaceutical industry and the British authorities over spending levels and NHS adoption.
The disagreement were exacerbated by arguments that US consumers were charged several times more for the equivalent treatments than consumers in the Britain and the EU.
Recently, several large drug company projects in the UK have been delayed or scrapped, while major investments have been directed toward US facilities.
The Science Minister acknowledged that the NHS needed to invest a greater share on drugs, noting that its budget allocation on drugs had declined as a proportion of its resources over the past decade.
